Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy

Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for recommending its use for the treatment of moderate-to-severe disease is still controversial among clinical guidelines. We performed a nationwide, registry-based study including all Italian hospitalized patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Pierluigi, Tacconelli, Evelina, Olimpieri, Pier Paolo, Celant, Simone, Colatrella, Antonietta, Tomassini, Luca, Palù, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228114/
https://www.ncbi.nlm.nih.gov/pubmed/35746668
http://dx.doi.org/10.3390/v14061197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228114/
https://www.ncbi.nlm.nih.gov/pubmed/35746668
http://dx.doi.org/10.3390/v14061197

Ejemplares similares